NASDAQ:GYRE Gyre Therapeutics (GYRE) Stock Price, News & Analysis $8.21 +0.10 (+1.23%) As of 12:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Gyre Therapeutics Stock (NASDAQ:GYRE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Gyre Therapeutics alerts:Sign Up Key Stats Today's Range$8.05▼$8.2650-Day Range$6.65▼$8.3352-Week Range$6.11▼$19.00Volume31,388 shsAverage Volume162,972 shsMarket Capitalization$790.73 millionP/E Ratio821.82Dividend YieldN/APrice Target$18.00Consensus RatingBuy Company Overview Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Read More Gyre Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScoreGYRE MarketRank™: Gyre Therapeutics scored higher than 24% of companies evaluated by MarketBeat, and ranked 844th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingGyre Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGyre Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Gyre Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Gyre Therapeutics is 812.31, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.52.Price to Earnings Ratio vs. SectorThe P/E ratio of Gyre Therapeutics is 812.31, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 30.80.Price to Book Value per Share RatioGyre Therapeutics has a P/B Ratio of 6.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Gyre Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.38% of the float of Gyre Therapeutics has been sold short.Short Interest Ratio / Days to CoverGyre Therapeutics has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in Gyre Therapeutics has recently increased by 2.21%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGyre Therapeutics does not currently pay a dividend.Dividend GrowthGyre Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.38% of the float of Gyre Therapeutics has been sold short.Short Interest Ratio / Days to CoverGyre Therapeutics has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in Gyre Therapeutics has recently increased by 2.21%, indicating that investor sentiment is decreasing. News and Social Media2.0 / 5News Sentiment0.58 News SentimentGyre Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Gyre Therapeutics this week, compared to 2 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Gyre Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 10.00% of the stock of Gyre Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 23.99% of the stock of Gyre Therapeutics is held by institutions.Read more about Gyre Therapeutics' insider trading history. Receive GYRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GYRE Stock News HeadlinesGyre Therapeutics (NASDAQ:GYRE) Now Covered by HC WainwrightAugust 28 at 2:19 AM | americanbankingnews.comGyre Therapeutics initiated with a Buy at H.C. WainwrightAugust 27 at 2:34 AM | msn.comWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was projected. According to Porter Stansberry, this is panic-level borrowing… and a clear sign we’re nearing America’s financial breaking point. In his latest emergency briefing, Porter outlines why the cracks in our system are widening fast—and how Trump’s policies may be accelerating the collapse. More importantly, he reveals three moves you can make now to protect and potentially grow your wealth before the levee breaks.August 28 at 2:00 AM | Porter & Company (Ad)HC Wainwright & Co. Initiates Coverage of Gyre Therapeutics (GYRE) with Buy RecommendationAugust 27 at 2:34 AM | msn.comGyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of DirectorsAugust 22, 2025 | globenewswire.comGyre Therapeutics' (NASDAQ:GYRE) Profits Appear To Have Quality IssuesAugust 18, 2025 | uk.finance.yahoo.comUS Undiscovered Gems 3 Promising Small Caps with Strong PotentialAugust 13, 2025 | finance.yahoo.comGyre Therapeutics Inc.: Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership UpdateAugust 12, 2025 | finanznachrichten.deSee More Headlines GYRE Stock Analysis - Frequently Asked Questions How have GYRE shares performed this year? Gyre Therapeutics' stock was trading at $12.10 at the beginning of the year. Since then, GYRE shares have decreased by 33.3% and is now trading at $8.0750. How were Gyre Therapeutics' earnings last quarter? Gyre Therapeutics, Inc. (NASDAQ:GYRE) issued its earnings results on Monday, August, 11th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by $0.01. The company had revenue of $26.77 million for the quarter, compared to analyst estimates of $30.80 million. Gyre Therapeutics had a net margin of 4.08% and a trailing twelve-month return on equity of 7.67%. Who are Gyre Therapeutics' major shareholders? Gyre Therapeutics' top institutional shareholders include Geode Capital Management LLC (0.43%), SBI Securities Co. Ltd. (0.25%), American Century Companies Inc. (0.01%) and MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. (0.01%). Insiders that own company stock include Songjiang Ma and Nassim Usman. View institutional ownership trends. How do I buy shares of Gyre Therapeutics? Shares of GYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Gyre Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gyre Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Palo Alto Networks (PANW) and Invesco QQQ (QQQ). Company Calendar Last Earnings8/11/2025Today8/28/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GYRE Previous SymbolNASDAQ:GYRE CIK1124105 Webwww.catalystbiosciences.com Phone(619) 949-3681Fax336-480-2107Employees40Year FoundedN/APrice Target and Rating Average Price Target for Gyre Therapeutics$18.00 High Price Target$18.00 Low Price Target$18.00 Potential Upside/Downside+119.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)$0.01 Trailing P/E Ratio821.82 Forward P/E RatioN/A P/E GrowthN/ANet Income$12.09 million Net Margins4.08% Pretax Margin11.33% Return on Equity7.67% Return on Assets6.19% Debt Debt-to-Equity RatioN/A Current Ratio5.40 Quick Ratio4.87 Sales & Book Value Annual Sales$102.19 million Price / Sales7.74 Cash Flow$0.21 per share Price / Cash Flow39.29 Book Value$1.34 per share Price / Book6.13Miscellaneous Outstanding Shares96,313,000Free Float86,682,000Market Cap$790.73 million OptionableNo Data Beta1.80 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:GYRE) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredChase, Bank of America, Wells Fargo Preparing for BIG ChangeThanks to this brand-new law #S.1582 signed by President Trump… Jeff Brown believes the largest banks in Am...Brownstone Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.